Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuro-oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SEMA3A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SEMA3A ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SEMA3A Products |
| Gene Delivery | SEMA3A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SEMA3A Products |
| Benchmark Ab | Anti-SEMA3A (Sequence of Clinical Biosimilar) Recombinant positive control. |
View SEMA3A Products |
| Validator | SEMA3A siRNA Set For knockdown verification. |
View SEMA3A Products |
| Related Target A | NRP1 (Neuropilin-1) Primary obligate co-receptor mediating SEMA3A signaling. |
View NRP1 Products |
| Related Target B | PLXNA1 (Plexin-A1) Signal transducing subunit of the SEMA3A receptor complex. |
View PLXNA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SEMA3A Homodimerization Requirements | HEK293 expressed recombinant SEMA3A-Fc to preserve native disulfide-linked dimeric conformation. |
| NRP1 Co-receptor binding assay | High-purity human NRP1 and PLXNA1 extracellular domains available with >95% purity for competitive SPR/BLI assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live SEMA3A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SEMA3A therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific constructs and combination therapies in oncology and vascular diseases. As first-generation therapies reach the clinic, the next wave of R&D is targeting the reversal of tumor immunosuppression and the restoration of axonal regeneration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Sanofi, Eisai | Neuropathic Pain, Macular Degeneration | Blocking Assay (Need high-purity homodimeric SEMA3A-Fc) |
| Bispecific Antibody | Biotech Innovators | Immuno-Oncology (Solid Tumors) | Dual-targeting Validation (Need cross-reactive SEMA3A and PD-L1/VEGF antigens) |
| Small Molecule inhibitors | Academic Spin-offs | Spinal Cord Injury, Neuroregeneration | Selectivity Assay (Need Mutant vs WT Proteins and SEMA family panels) |